urothelial carcinoma

You have access
Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma
TAKESHI SANO, RIHITO AIZAWA, KATSUHIRO ITO, KIYONAO NAKAMURA, TAKASHI OGATA, MASASHI TAKEDA, AKIHIRO HAMADA, TAKASHI MATSUOKA, JIN KONO, YUKI KITA, KIMIHIKO MASUI, TAKAYUKI GOTO, ATSURO SAWADA, SHUSUKE AKAMATSU, OSAMU OGAWA, TAKASHI MIZOWAKI and TAKASHI KOBAYASHI

Anticancer Research May 2023, 43 (5) 2119-2126; DOI: https://doi.org/10.21873/anticanres.16373
Open Access
Expression of Eukaryotic Translation Initiation Factors in the Urothelial Carcinoma of the Bladder
JETON LUZHA, NORBERT NASS, PIOTR CZAPIEWSKI, NICOLAS SCHROEDER, THOMAS KALINSKI, MARTIN SCHOSTAK, CHRISTOPH SCHATZ, BURKHARD JANDRIG and JOHANNES HAYBAECK

Anticancer Research April 2023, 43 (4) 1437-1448; DOI: https://doi.org/10.21873/anticanres.16292
You have access
Artesunate Exhibits Synergy With Cisplatin and Cytotoxicity for Upper Tract and Bladder Urothelial Carcinoma Cells
SAN-YUAN CHEN, CHUN-NUN CHAO, HSIN-YI HUANG, PEI-WEN ZHAO and CHIUNG-YAO FANG

Anticancer Research March 2023, 43 (3) 1175-1184; DOI: https://doi.org/10.21873/anticanres.16263
You have access
First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study
JIAN-RI LI, SHIAN-SHIANG WANG, KEVIN LU, CHAUN-SHU CHEN, CHEN-LI CHENG, SHENG-CHUN HUNG, KUN-YUAN CHIU, CHIANN YI HSU and CHENG-KUANG YANG

Anticancer Research March 2023, 43 (3) 1331-1339; DOI: https://doi.org/10.21873/anticanres.16281
You have access
Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab
IKKO TOMISAKI, MIRII HARADA, SHIGERU SAKANO, MICHIKAZU TERADO, RYOICHI HAMASUNA, SHUJI HARADA, HIROOMI MATSUMOTO, SOICHIRO AKASAKA, YUJIRO NAGATA, AKINORI MINATO, KEN-ICHI HARADA and NAOHIRO FUJIMOTO

Anticancer Research January 2023, 43 (1) 269-274; DOI: https://doi.org/10.21873/anticanres.16159
You have access
Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer
SATOSHI INOUE, NAOTO SASSA, HIDEJI KAWANISHI, YURI YUGUCHI, TOMOHIDE SUZUKI, JUN NAGAYAMA, HIROTAKA MATSUI, YUDAI MIYATA, YUYA SOEDA, KOSUKE TOCHIGI, YUSHI YAMAUCHI, MOTOHIRO MAEDA, IKUO KOBAYASHI, RYOHEI HATTORI, YOSHIHISA MATSUKAWA and MASASHI KATO

Anticancer Research July 2022, 42 (7) 3627-3636; DOI: https://doi.org/10.21873/anticanres.15851
You have access
Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma
IKKO TOMISAKI, MIRII HARADA, AKINORI MINATO, YUJIRO NAGATA, RIEKO KIMURO, KATSUYOSHI HIGASHIJIMA, KENICHI HARADA and NAOHIRO FUJIMOTO

Anticancer Research March 2022, 42 (3) 1629-1634; DOI: https://doi.org/10.21873/anticanres.15638
You have access
Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma
RYO KURASHINA, KIYOHIRO ANDO, MASAHARU INOUE, KEITA IZUMI, RIKO MARUYAMA, KOUKI MITANI, HISANORI TAKENOBU, MASAYUKI HARUTA, TOSHIHIKO IIZUKA, TAKEHIKO KAMIJO and YUKIO KAGEYAMA

Anticancer Research February 2022, 42 (2) 1131-1136; DOI: https://doi.org/10.21873/anticanres.15576
You have access
Prognostic Value of Squamous Differentiation in Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy
AKINORI MINATO, HIROTSUGU NOGUCHI, RIEKO KIMURO, HARADA MIRII, NAGATA YUJIRO, YOSHITAKA HASEGAWA, IKKO TOMISAKI, KENICHI HARADA and NAOHIRO FUJIMOTO

Anticancer Research January 2022, 42 (1) 263-269; DOI: https://doi.org/10.21873/anticanres.15481
You have access
Nuclear Factor IA Is Down-regulated in Muscle-invasive and High-grade Bladder Cancers
MACIEJ KACZOROWSKI, JOANNA MATYSIAK, PAWEL KIELB, BARTOSZ MALKIEWICZ and AGNIESZKA HALON

Anticancer Research January 2022, 42 (1) 493-500; DOI: https://doi.org/10.21873/anticanres.15507

Main menu

User menu

Search

urothelial carcinoma

Pages